Pathos AI Secures $237M in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline
Insider Brief PRESS RELEASE — Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers S…
Read the full story at AI Insider ↗